- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05751967
Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis
March 3, 2023 updated by: Han Ying, Xijing Hospital of Digestive Diseases
A Prospective, Multi-center, Randomized, Double-blind, Placebo-controlled Study: Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis and an Inadequate Response to Ursodeoxycholic Acid
Current treatment guidelines recommend ursodeoxycholic acid (UDCA) as the first-line treatment for new-diagnosed primary biliary cholangitis (PBC) patients.
However, up to 40% patients are insensitive to UDCA monotherapy, and evaluation of UDCA response at 12 months may result in long period of ineffective treatment.
We aimed to develop a new criterion to reliably identify non-response patients much earlier.
Recently, our team designed and validated a new early criterion for distinguishing high-risk PBC patients in a Chinese population for the first time.
Our data indicated that PBC patients with ALP ≤ 2.5 × ULN, AST ≤ 2 × ULN, and TBIL ≤ 1 × ULN (Xi'an criterion) after 1 month UDCA treatment were likely to have better prognosis.
It can be readily applied in the rapid identification of PBC patients who require additional therapeutic approaches.
However, whether it is reasonable to apply it to the response definition of clinical research, and the guidance of PBC management and choice of second-line treatment, further research is needed.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
This is a multi-center, randomized, placebo-controlled, parallel-group study that will assess the efficacy and safety of fenofibrate in patients with PBC who had an inadequate biochemical response to UDCA, as defined by the Xi'an criteria.
Fenofibrate or placebo 200 mg will be daily administered in combination with UDCA 13-15 mg/kg/d for 48 months.
Patient safety will be monitored.
Primary end-point will be the percentage of patients with a complete normalization of the ALP and TBIL.
Secondary endpoints will include the percentage of drug-related adverse events, survival rates without liver transplantation or liver decompensation, time course of non-invasive liver fibrosis measurements (LSM), time course of endoscopic, ultrasound, and biochemical features of portal hypertension, time course of pruritus and of quality of life using validated scales.
Study Type
Interventional
Enrollment (Anticipated)
150
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Ying Han
- Phone Number: +86-29-84771539
- Email: hanying1@fmmu.edu.cn
Study Contact Backup
- Name: Yulong Shang
- Phone Number: +86 18629661032
- Email: shangyl870222@163.com
Study Locations
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710032
- Recruiting
- Ying han
-
Contact:
- Ying Han
- Phone Number: +86-29-84771539
- Email: hanying1@fmmu.edu.cn
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Must have provided written informed consent;
- Age 18-75 years;
- BMI 17-28 kg/m2
Male or female with a diagnosis of PBC, by at least two of the following criteria:
- History of AP above ULN for at least six months;
- Positive AMA titers (>1/40 on immunofluorescence or M2 positive by enzyme linked immunosorbent assay (ELISA) or positive PBC-specific antinuclear antibodies;
- Documented liver biopsy result consistent with PBC.
- Incomplete response to UDCA defined by Xi'an criteria (ALP >2.5× ULN, AST>2×ULN or TBIL>1×ULN) after UDCA treatment for 4-6 weeks with at least one abnormal test in ALP or TBIL.
Exclusion Criteria:
- History or presence of other concomitant liver diseases.
- ALT/AST > 5×ULN, TBIL > 3×ULN.
- If female: known pregnancy, or has a positive urine pregnancy test (confirmed by a positive serum pregnancy test), or lactating.
- Allergic to fenofibrate or ursodeoxycholic acid.
- Taking hepatotoxic drugs (e.g., dapsone, erythromycin, fluconazole, ketoconazole, rifampicin) for more than 2 weeks within 6 months, and long-term hormonal users.
- Recurrent variceal bleeding, poorly controlled hepatic encephalopathy or refractory ascites.
- Patients with a history of severe cardiac, cerebrovascular, renal, respiratory disease or functional failure, and psychiatric disorders (including those due to alcohol and drug abuse).
- Creatinine >1.5×ULN and creatinine clearance <60 ml/min.
- Currently using statins (such as pravastatin, fluvastatin, and simvastatin), other fibrates (such as gemfibrozil and bezafibrate), and drugs structurally similar to fenofibrate (like ketoprofen).
- Planned to receive an organ transplant or an organ transplant recipient.
- Needing Liver transplantation within 1 year according to the Mayo Rick score.
- Any other condition(s) that would compromise the safety of the subject or compromise the quality of the clinical study, as judged by the Investigator.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
1 tablet/ day
|
1 tablet/ day
Other Names:
|
Experimental: Fenofibrate
200 mg/day
|
200 mg/day
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of patients with complete biochemical response
Time Frame: 48 weeks
|
The normalisation of Alkaline Phosphatase (ALP) and total bilirubin (TBIL).
|
48 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of patients having biological or clinical adverse events
Time Frame: 4, 12, 24, 36, and 48 weeks
|
Increase of creatinine
|
4, 12, 24, 36, and 48 weeks
|
Percentage of patients having biological or clinical adverse events
Time Frame: 4, 12, 24, 36, and 48 weeks
|
Increase of creatine kinase
|
4, 12, 24, 36, and 48 weeks
|
Survival without transplantation and hepatic impairment
Time Frame: 48 weeks
|
Occurrence of ascites, variceal bleeding, hepatic encephalopathy, liver-transplantation, or death.
|
48 weeks
|
Percentage of patients having complete biochemical response
Time Frame: 4, 12, 24, 36, and 48 weeks
|
The normalisation of Alkaline Phosphatase (ALP) and total bilirubin (TBIL) at 4, 12, 24, and 36 weeks.
|
4, 12, 24, 36, and 48 weeks
|
Assessment of the fatigue and the quality of life
Time Frame: 4, 12, 24, 36, and 48 weeks
|
Change from baseline in primary biliary cholangitis -40 (PBC-40) quality of life (QoL) questionnaire scores.
|
4, 12, 24, 36, and 48 weeks
|
Assessment of the fatigue and the quality of life
Time Frame: 4, 12, 24, 36, and 48 weeks
|
Change from baseline in pruritus as assessed by Visual Analogue Scale (VAS) total score for fatigue and pruritus.
|
4, 12, 24, 36, and 48 weeks
|
Evolution of the biological markers of the hepatic function or being in the usual prognostic scores
Time Frame: 4, 12, 24, 36, and 48 weeks
|
Mayo score at 4, 12, 24, 36, and 48 weeks
|
4, 12, 24, 36, and 48 weeks
|
Evolution of the biological markers of the hepatic function or being in the usual prognostic scores
Time Frame: 4, 12, 24, 36, and 48 weeks
|
Child-Puch score at 4, 12, 24, 36, and 48 weeks
|
4, 12, 24, 36, and 48 weeks
|
Evolution of the biological markers of the hepatic function or being in the usual prognostic scores
Time Frame: 4, 12, 24, 36, and 48 weeks
|
MELD score at 4, 12, 24, 36, and 48 weeks
|
4, 12, 24, 36, and 48 weeks
|
Evolution of the biological markers of the hepatic function or being in the usual prognostic scores
Time Frame: 48 weeks
|
GLOBE-PBC score at 48 weeks
|
48 weeks
|
Evolution of the biological markers of the hepatic function or being in the usual prognostic scores
Time Frame: 48 weeks
|
UK-PBC score at 48 weeks
|
48 weeks
|
Percentage of patients having biological or clinical adverse events
Time Frame: 4, 12, 24, 36, and 48 weeks
|
Increase of Blood urea nitrogen
|
4, 12, 24, 36, and 48 weeks
|
Percentage of patients having biological or clinical adverse events
Time Frame: 4, 12, 24, 36, and 48 weeks
|
Increase of ALT and AST.
|
4, 12, 24, 36, and 48 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Ying Han, Doctor, Xijing hospital, Air force Military Medical University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 22, 2023
Primary Completion (Anticipated)
December 1, 2024
Study Completion (Anticipated)
December 1, 2025
Study Registration Dates
First Submitted
December 13, 2022
First Submitted That Met QC Criteria
February 20, 2023
First Posted (Actual)
March 2, 2023
Study Record Updates
Last Update Posted (Estimate)
March 6, 2023
Last Update Submitted That Met QC Criteria
March 3, 2023
Last Verified
February 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Liver Diseases
- Fibrosis
- Biliary Tract Diseases
- Bile Duct Diseases
- Cholestasis, Intrahepatic
- Cholestasis
- Liver Cirrhosis
- Cholangitis
- Liver Cirrhosis, Biliary
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites
- Gastrointestinal Agents
- Hypolipidemic Agents
- Lipid Regulating Agents
- Cholagogues and Choleretics
- Fenofibrate
- Ursodeoxycholic Acid
Other Study ID Numbers
- KY20222274-C-1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary Biliary Cholangitis
-
Medical University of WarsawNational Science Centre, PolandRecruitingPrimary Sclerosing Cholangitis (PSC)Poland
-
Mayo ClinicActive, not recruiting
-
Cascade Pharmaceuticals, IncCovanceCompletedPrimary Sclerosing Cholangitis (PSC)United States
-
HighTide Biopharma Pty LtdCompletedPrimary Sclerosing Cholangitis (PSC)United States, Canada
-
Intercept PharmaceuticalsCompletedPrimary Sclerosing Cholangitis (PSC)United States, Italy
-
Mirum Pharmaceuticals, Inc.CompletedPrimary Sclerosing Cholangitis (PSC)United States, United Kingdom, Canada
-
Mayo ClinicCompletedPrimary Sclerosing Cholangitis (PSC)United States
-
IpsenRecruitingPrimary Biliary Cholangitis (PBC)United States, Spain, Romania
-
GenfitCompletedPrimary Biliary Cholangitis (PBC)United States, United Kingdom, France, Germany, Spain
-
Sun Yat-sen UniversityUnknown
Clinical Trials on Placebo Combined With Ursodeoxycholic Acid
-
West China HospitalUnknownHepatitis | Autoimmune | Primary Biliary CholangitisChina
-
Turku University HospitalCompletedPregnancy | Intrahepatic CholestasisFinland
-
HaEmek Medical Center, IsraelUnknown
-
Mitsubishi Tanabe Pharma CorporationCompletedChronic Hepatitis CJapan
-
GlaxoSmithKlineCompleted
-
Daewoong Pharmaceutical Co. LTD.Completed
-
University of OxfordOregon Health and Science University; University of Washington; University of... and other collaboratorsActive, not recruitingSEPSIS | MALNUTRITION, CHILDBangladesh, Uganda, Malawi, Kenya
-
Assistance Publique - Hôpitaux de ParisAxcan PharmaUnknownAdenomatous Polyposis Coli, FamilialFrance
-
Tanta UniversityRecruitingRheumatoid ArthritisEgypt
-
Ibrahim MohamedCompleted